Biotech Values

[DewDiligence]

ANDS CC notes (addendum): CEO Steve Worland may have inadvertently signaled that the purported partnership interest in ANA598 is not genuine.

In reply to a question about what the next ANA598 trial will look like, Worland answered by saying that Anadys was leaning toward the design detailed in #msg-37270158.

If there were serious interest in ANA598 from prospective partners, I don’t think Worland would have answered the question like that. This is a case of the dog that didn’t bark!